Related Experiment Video
Updated: May 3, 2026

Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise
Published on: July 14, 2023
Clinical value of tapentadol extended-release in painful diabetic peripheral neuropathy
Bansri Desai1, Erin Freeman, Ellen Huang
1University of Maryland School of Pharmacy, 300 West Lombard St, Apt 413, Baltimore, MD 21201, USA.
Abstract:
Painful diabetic peripheral neuropathy is difficult to treat, partially because the underlying mechanism of pain is not fully understood. Various treatment guidelines recommend first-line agents, such as α2-δ ligands, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants but combination therapy of alternative agents including opiates is often warranted. Tapentadol extended-release has a novel dual mechanism of action; it is both a mu-opioid receptor agonist and a norephinephrine reuptake inhibitor. It has been in the spotlight since it was FDA-approved specifically for the treatment of painful diabetic peripheral neuropathy in 2012. Previous reviews of tapentadol have focused on chronic pain. The purpose of this review article is to assess the efficacy and safety of tapentadol extended-release in adult populations with painful diabetic peripheral neuropathy and provide guidance for formulary decisions.
Related Concept Videos
Diabetic Neuropathy
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Diabetic Foot Ulcer

